second line of chemotherapy
Showing 1 - 25 of >10,000
Recurrent or Progressive Glioblastoma Trial in Detroit (Bevacizumab, Bevacizumab with chemo, Fractionated radiosurgery)
Completed
- Recurrent or Progressive Glioblastoma
- Bevacizumab
- +2 more
-
Detroit, MichiganHenry Ford Health System
Jan 30, 2023
NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)
Completed
- Non-Small Cell Lung Cancer
- Brain Neoplasms
- bevacizumab
- +2 more
- (no location specified)
Dec 9, 2022
Advanced Gastric Adenocarcinoma Trial in Seoul (AZD1775, paclitaxel)
Completed
- Advanced Gastric Adenocarcinoma
-
Seoul, Korea, Republic ofSamsung Medical center
Jun 13, 2022
Recurrent Liver Cancer After Liver Transplantation Trial (Hepatic arterial infusion chemo + Atezolizumab and bevacizumab)
Not yet recruiting
- Recurrent Liver Cancer After Liver Transplantation
- Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
- (no location specified)
Apr 17, 2023
Breast Cancer Trial in Detroit (biological, drug, other)
Terminated
- Breast Cancer
- HER2Bi-armed activated T cells
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Nov 29, 2022
Pancreatic Cancer Trial in Milwaukee (First-line Chemotherapy, Second-line Chemotherapy, Chemoradiation)
Recruiting
- Pancreatic Cancer
- First-line Chemotherapy
- +2 more
-
Milwaukee, WisconsinFroedtert & the Medical College of Wisconsin
Jul 29, 2022
Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC
Completed
- Non-small Cell Lung Cancer
- Lazertinib
- Platinum-based Chemotherapy
- (no location specified)
May 8, 2023
Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)
Recruiting
- Immunotherapy
- Second-line Treatment
-
Guizhou, ZunYi, ChinaThe Second Affiliated Hospital of Zunyi Medical University
Jun 14, 2023
Ovarian Cancer Trial in Brazil (Palbociclib 125mg, Letrozole 2.5mg)
Active, not recruiting
- Ovarian Cancer
- Palbociclib 125mg
- Letrozole 2.5mg
-
Belo Horizonte, Minas Gerais, Brazil
- +4 more
Feb 10, 2022
NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))
Withdrawn
- NSCLC Stage IV
- combination regimen tremelimumab /durvalumab
- platinum-based chemotherapy (SoC)
-
Gauting, GermanyAsklepios Fachkliniken München-Gauting
Sep 26, 2022
Metastatic Gastric Adenocarcinoma, Second Line, Chemo Trial (nal-IRI /Experimental, Ramucirumab /Experimental,
Not yet recruiting
- Metastatic Gastric Adenocarcinoma
- +2 more
- nal-IRI /Experimental
- +2 more
- (no location specified)
Jun 25, 2023
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,
Not yet recruiting
- Pancreatic Acinar Cell Carcinoma
- +6 more
- Nab paclitaxel
- +5 more
- (no location specified)
Oct 30, 2023
Gastric or Esophagogastric Junction Adenocarcinoma Trial (nimotuzumab plus paclitaxel, plus paclitaxel)
Not yet recruiting
- Gastric or Esophagogastric Junction Adenocarcinoma
- nimotuzumab plus paclitaxel
- placebo plus paclitaxel
- (no location specified)
Aug 3, 2023
Small Cell Lung Cancer, Angiogenesis, Chemo Effect Trial (Surufatinib, Irinotecan)
Not yet recruiting
- Small Cell Lung Cancer
- +2 more
- (no location specified)
Nov 27, 2022
United States Using Electronic Medical Records to Assess
Completed
- Squamous Non-small Cell Lung Cancer
- Second line (2L) afatinib
- Second line chemotherapy
-
Dublin, OhioCardinal Health Specialty Solutions
Dec 22, 2021
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer Trial in Boston (MRI)
Recruiting
- Breast Cancer
- +5 more
- MRI
-
Boston, MassachusettsBrigham and Women's Hospital
Dec 9, 2022
Metastatic Colorectal Cancer Trial in China (Fruquintinib+ chemo, Bevacizumab+ chemo)
Not yet recruiting
- Metastatic Colorectal Cancer
- Fruquintinib+ chemotherapy
- Bevacizumab+ chemotherapy
-
Putian, Fujian, China
- +11 more
Sep 27, 2022
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung
Not yet recruiting
- Advanced Non-squamous Non-small-cell Lung Cancer
- +2 more
- pembrolizumab
- +2 more
-
Beijing, Beijing, ChinaPeking University First Hospital Ethics Committee
Sep 10, 2023
Stomach Cancer Trial in Beijing (KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection)
Recruiting
- Stomach Cancer
- KN026/Placbo Injection
- +3 more
-
Beijing, ChinaChinese PLA General Hospital
Jun 16, 2022
Esophagus Squamous Cell Carcinoma Trial in Beijing (Palbociclib, Afatinib)
Recruiting
- Esophagus Squamous Cell Carcinoma
-
Beijing, Beijing, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medic
May 17, 2023
Colorectal Cancer Trial in Hangzhou (Surufatinib, Toripalimab, chemo)
Recruiting
- Colorectal Cancer
- Surufatinib
- +2 more
-
Hangzhou, Zhejiang, ChinaFirst affiliated hospital, Zhejiang University
Feb 26, 2022